SYSTEMATIC REVIEW WITH META-ANALYSIS
Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia
Zobair M. Younossi,
Linda Henry, Janus P. Ong, Atsushi Tanaka, Yuichiro Eguchi, Masashi Mizokami, Young-Suk Lim, Yock Young Dan, Ming-Lung Yu, Maria Stepanova,
Corresponding Author
Zobair M. Younossi
Falls Church, Virginia
Correspondence
Zobair M. Younossi, Betty and Guy Beatty Center for Integrated Research, Claude Moore Health Education and Research Building, Falls Church, VA.
Email: [email protected]
Search for more papers by this authorZobair M. Younossi,
Linda Henry, Janus P. Ong, Atsushi Tanaka, Yuichiro Eguchi, Masashi Mizokami, Young-Suk Lim, Yock Young Dan, Ming-Lung Yu, Maria Stepanova,
Corresponding Author
Zobair M. Younossi
Falls Church, Virginia
Correspondence
Zobair M. Younossi, Betty and Guy Beatty Center for Integrated Research, Claude Moore Health Education and Research Building, Falls Church, VA.
Email: [email protected]
Search for more papers by this authorAuthors’ complete affiliations are listed in Appendix section.
As part of AP&T's peer-review process, a technical check of this meta-analysis was performed by Dr Y Yuan. The Handling Editor for this article was Professor Grace Wong, and it was accepted for publication after full peer-review.
Funding information This study is funded by Gilead Sciences.
SUMMARY
Background
Although the prevalence of extrahepatic manifestations of chronic hepatitis C virus (HCV) infection has been reported from Western countries, their prevalence in East Asian countries is not well known.
Aim
To perform a systematic review to quantify the prevalence of selected extrahepatic manifestations of HCV among patients from East Asia.
Methods
Medline, CINAHL, EMBASE, Cochrane and country-specific databases were reviewed according to standard guidelines for meta-analyses. Only articles with patients from East Asian countries were included.
Results
After review, 34 articles were selected (Japan = 9; China = 5, Korea = 3, Taiwan = 16, multiple countries = 1) with 646 228 subjects, 66 436 with HCV. Mean age for HCV-infected patients was 56 years (range 41-72 years), 50% were male (range 26%-73%). The pooled prevalence of type 2 diabetes in East Asian HCV patients was 19.0% (95% confidence interval 15.6%-22.9%) (n = 19 studies) with an increased risk when compared to non-HCV: odds ratio (OR) 1.58 (1.28-1.94). The prevalence of chronic kidney disease in HCV was 9.2% (5.0%-16.2%) (n = 7 studies), also with a significantly increased risk: OR=1.98 (1.41-2.77). Pooled prevalence of cardiovascular disease in HCV was 8.6% (3.5%-19.9%) (n = 6 studies), also with an increased risk: OR = 1.55 (1.21-1.98). The prevalence of lichen planus in HCV was 8.9% (3.6%-20.6%) (n = 6 studies) while the prevalence of rheumatoid arthritis was 4.5% (0.6%-25.7%) (n = 4 studies).
Conclusions
These data show increased risk of developing extrahepatic manifestations in East Asian patients with HCV. Both hepatic and extrahepatic manifestations of the infection should be used to accurately determine the total burden of the disease in the region.
Supporting Information
| Filename | Description |
|---|---|
| apt15131-sup-0001-Supinfo.docxWord document, 2.7 MB |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1 World Health Organization (WHO) Hepatitis C Virus Fact Sheet, October 2017. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed August 3, 2018.
- 2Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016; 388: 1081-1088.
- 3Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013; 10: 553-562.
- 4Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016; 22: 7824-7840.
- 5Bennett H, Waser N, Johnston K, et al. A review of the burden of hepatitis C virus infection in China, Japan. South Korea and Taiwan. Hepatol Int. 2015; 9: 378-390.
- 6Lim SG, Dan YY. A 2015 roadmap for the management of hepatitis C virus infections in Asia. Korean J Intern Med. 2015; 30: 423-433.
- 7Kim KA. Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Indications for Treatment. Korean J Gastroenterol. 2016; 67: 123-126.
- 8Stepanova M, Younossi ZM. Economic burden of hepatitis C infection. Clin Liver Dis. 2017; 21: 579-594.
- 9El-Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology. 2002; 36: 1439-1445.
- 10Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis. 2014; 46(Suppl. 5): S165-S173.
- 11Basseri B, Yamini D, Chee G, Enayati PD, Tran T, Poordad F. Comorbidities associated with the increasing burden of hepatitis C infection. Liver Int. 2010; 30: 1012-1018.
- 12Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol. 2010; 8: 1017-1029.
- 13Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology. 2016; 150: 1599-1608.
- 14Cacoub P, Buggisch P, Carrión JA, et al. Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe. J Viral Hepat. 2018; 25: 811-817.
- 15Moher D, Liberati A, Tetzlaff J, Altman DG; The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6: e1000097.
- 16Wells GA, Shea B, O'connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 10/8/2018.
- 17Nagao Y, Kawasaki K, Sata M. Insulin resistance and lichen planus in patients with HCV-infectious liver diseases. J Gastroenterol Hepatol. 2008; 23: 580-585.
- 18Wang CS, Wang ST, Yao WJ, Chang TT, Chou P. Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. Am J Epidemiol. 2007; 166: 196-203.
- 19Imazeki F, Yokosuka O, Fukai K, Kanda T, Kojima H, Saisho H. Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients. Liver Int. 2008; 28: 355-362.
- 20Iwata H, Matsuo K, Takeuchi K, Kishi Y, Murashige N, Kami M. High incidences of malignant lymphoma in patients infected with hepatitis B or hepatitis C virus. Haematologica. 2004; 89: 368-370.
- 21Kang J, Cho JH, Suh CW, Lee DH, Oh HB. High prevalence of hepatitis B and hepatitis C virus infections in Korean patients with hematopoietic malignancies. Ann Hematol. 2011; 90: 159-164.
- 22Ryu JK, Lee SB, Hong SJ, Lee S. Association of chronic hepatitis C virus infection and diabetes mellitus in Korean patients. Korean J Intern Med. 2001; 16: 18-23.
- 23Wang LF, Wu CH, Shan Y, et al. Prevalence of abnormal glycometabolism in patients with chronic hepatitis C and related risk factors in China. Chin Med J (Engl). 2011; 124: 183-188.
- 24Cheng Z, Zhou B, Shi X, et al. Extrahepatic manifestations of chronic hepatitis C virus infection: 297 cases from a tertiary medical center in Beijing, China. Chin Med J (Engl). 2014; 127: 1206-1210.
- 25Huang JF, Dai CY, Hwang SJ, et al. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication. Am J Gastroenterol. 2007; 102: 1237-1243.
- 26Matsumori A, Ohashi N, Hasegawa K, Sasayama S, Eto T, Imaizumi T, et al. Hepatitis C virus infection and heart diseases: a multicenter study in Japan. Jpn Circ J. 1998; 62: 389-391.
- 27Bo Q, Orsenigo R, Wang J, Griffel L, Brass C. Glucose abnormalities in Asian patients with chronic hepatitis C. Drug Des Devel Ther. 2015; 9: 6009-6017.
- 28Lin MS, Guo SE, Chen MY, et al. The impact of hepatitis C infection on ischemic heart disease via ischemic electrocardiogram. Am J Med Sci. 2014; 347: 478-484.
- 29Nagao Y, Kawaguchi T, Tanaka K, Kumashiro R, Sata M. Extrahepatic manifestations and insulin resistance in an HCV hyperendemic area. Int J Mol Med 2005; 16: 291-296.
- 30Liao CC, Su TC, Sung FC, Chou WH, Chen TL. Does hepatitis C virus infection increase risk for stroke? A population-based cohort study PLoS ONE. 2012; 7: e31527.
- 31Chen YC, Chiou WY, Hung SK, Su YC, Hwang SJ. Hepatitis C virus itself is a causal risk factor for chronic kidney disease beyond traditional risk factors: a 6-year nationwide cohort study across Taiwan. BMC Nephrol. 2013; 14: 187.
- 32Li WC, Lee YY, Chen IC, Wang SH, Hsiao CT, Loke SS. Age and gender differences in the relationship between hepatitis C infection and all stages of chronic kidney disease. J Viral Hepat. 2014; 21: 706-715.
- 33Nagao Y, Hanada S, Shishido S, et al. Insulin resistance and lichen planus in patients with HCV-infectious liver diseases. J Gastroenterol Hepatol. 2003; 18: 258-266.
- 34Nagao Y, Myoken Y, Katayama K, Tanaka J, Yoshizawa H, Sata M. Epidemiological survey of oral lichen planus among HCV-infected inhabitants in a town in Hiroshima Prefecture in Japan from 2000 to 2003. Oncol Rep. 2007; 18: 1177-1181.
- 35Chung CH, Yang YH, Chang TT, Shieh DB, Liu SY, Shieh TY. Relationship of oral lichen planus to hepatitis C virus in southern Taiwan. Kaohsiung J Med Sci. 2004; 20: 151-159.
- 36Su FH, Chang SN, Chen PC, et al. Positive association between hepatitis C infection and oral cavity cancer: a nationwide population-based cohort study in Taiwan. PLoS ONE. 2012; 7: e48109.
- 37Wang CC, Chang CT, Lin CL, Lin IC, Kao CH. Hepatitis C virus infection associated with an increased risk of deep vein thrombosis: a population-based cohort study. Medicine (Baltimore). 2015; 94: e1585.
- 38Lee JJ, Lin MY, Chang JS, et al. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS ONE. 2014; 9: e100790.
- 39Lee YH, Ji JD, Yeon JE, Byun KS, Lee CH, Song GG. Cryoglobulinaemia and rheumatic manifestations in patients with hepatitis C virus infection. Ann Rheum Dis. 1998; 57: 728-731.
- 40Su FH, Wu CS, Sung FC, et al. Chronic hepatitis C virus infection is associated with the development of rheumatoid arthritis: a nationwide population-based study in Taiwan. PLoS ONE. 2014; 9: e113579.
- 41Hsu YH, Muo CH, Liu CY, et al. Hepatitis C virus infection increases the risk of developing peripheral arterial disease: a 9-year population-based cohort study. J Hepatol. 2015; 62: 519-525.
- 42Ohsawa M, Kato K, Tanno K, et al. Seropositivity for anti-HCV core antigen is independently associated with increased all-cause, cardiovascular, and liver disease-related mortality in hemodialysis patients. J Epidemiol. 2011; 21: 491-499.
- 43Huang JF, Chuang WL, Yu ML, et al. Hepatitis C virus infection and metabolic syndrome—a community-based study in an endemic area of Taiwan. Kaohsiung J Med Sci. 2009; 25: 299-305.
- 44Wang Z, Du J, Zhao M, Page K, Xiao Z, Mandel JS. Hepatitis C virus infection is independently associated with depression among methadone maintenance treatment heroin users in China. Asia Pac Psychiatry. 2013; 5: 191-196.
- 45Zeng QL, Feng GH, Zhang JY, et al. Risk factors for liver-related mortality in chronic hepatitis C patients: a deceased case-living control study. World J Gastroenterol. 2014; 20: 5519-5526.
- 46Lee JJ, Lin MY, Yang YH, Lu SN, Chen HC, Hwang SJ. Association of hepatitis C and B virus infection with CKD in an endemic area in Taiwan: a cross-sectional study. Am J Kidney Dis. 2010; 56: 23-31.
- 47Arao M, Murase K, Kusakabe A, et al. Prevalence of diabetes mellitus in Japanese patients infected chronically with hepatitis C virus. J Gastroenterol. 2003; 38: 355-360.
- 48Lai TS, Lee MH, Yang HI, et al. Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study. Hepatology. 2017; 66: 784-793.
- 49Lin YJ, Shaw TG, Yang HI, et al. Chronic hepatitis C virus infection and the risk for diabetes: a community-based prospective study. Liver Int. 2017; 37: 179-186.
- 50Kamiza AB, Su FH, Wang WC, Sung FC, Chang SN, Yeh CC. Chronic hepatitis infection is associated with extrahepatic cancer development: a nationwide population-based study in Taiwan. BMC Cancer. 2016; 16: 861.
- 51Park H, Adeyemi A, Henry L, Stepanova M, Younossi Z. A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection. J Viral Hepat. 2015; 22: 897-905.
- 52Younossi ZM, Hepatitis C. Infection: a systemic disease. Clin Liver Dis. 2017; 21: 449-453.
- 53Park H, Chen C, Wang W, Henry L, Cook RL, Nelson DR. Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD. Hepatology. 2018; 67: 492-504.
- 54Zignego AL, Ramos-Casals M, Ferri C, et al. International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. Autoimmun Rev. 2017; 16: 523-541.
- 55Retamozo S, Brito-Zerón P, Quartuccio L, De Vita S, Ramos-Casals M. Introducing treat-to-target strategies of autoimmune extrahepatic manifestations of chronic hepatitis C virus infection. Expert Rev Clin Pharmacol. 2017; 10: 1085-1101.
- 56Degasperi E, Aghemo A, Colombo M. Treatment of extrahepatic manifestations of hepatitis C virus. Clin Liver Dis. 2017; 21: 631-643.
- 57Polo ML, Laufer N. Extrahepatic manifestations of HCV: the role of direct acting antivirals. Expert Rev Anti Infect Ther. 2017; 15: 737-746.
- 58Ramos-Casals M, Zignego AL, Ferri C, et al. Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. J Hepatol. 2017; 66: 1282-1299.
- 59Chang SC, Hung CT, Li SF, et al. Risk of nonpsychotic mental disorders development in antiviral-treated mentally healthy chronic hepatitis C patients: a population-based study. J Formos Med Assoc. 2015; 114: 829-834.
- 60Younossi Z, Papatheodoridis G, Cacoub P, et al. The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease. J Viral Hepat. 2018; 25: 6–14.
Citing Literature
